Signalling mechanisms regulating phenotypic changes in breast cancer cells

Bioscience Reports

Volumn 35, Issue , 2015, Pages

  Volinsky, Natalia ^a   McCarthy, Cormac J ^a   Von Kriegsheim, Alex ^a   Saban, Nina ^b   Okada Hatakeyama, Mariko ^b,c   Kolch, Walter ^a   Kholodenko, Boris N ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b Institute of Physical and Chemical Research   (Japan)

^c RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Breast cancer; Cell fate decisions; Lipid accumulation; MCF 7; MTOR; PI3 kinase; Receptor tyrosine kinases signalling pathways

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NEU DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; INSULIN; MULTIPROTEIN COMPLEX; NRG1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TUMOR PROTEIN;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CATALYSIS; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID SYNTHESIS; GLYCOLYSIS; HUMAN; HUMAN CELL; LIPID STORAGE; LIPOGENESIS; LIPOPHILICITY; MOLECULAR DYNAMICS; PHENOTYPE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BREAST TUMOR; FEMALE; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY;

MAMMALIA;

ATP CITRATE (PRO-S)-LYASE; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; NEUREGULIN-1; PHOSPHATIDYLINOSITOL 3-KINASES; TOR SERINE-THREONINE KINASES;

EID: 85017330182     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20140172     Document Type: Article

References (77)

1. Marshall, C.J. (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185 CrossRef PubMed
2. Sabbagh, Jr, W., Flatauer, L.J., Bardwell, A.J. and Bardwell, L. (2001) Specificity of MAP kinase signaling in yeast differentiation involves transient versus sustained MAPK activation. Mol. Cell 8, 683-691 CrossRef PubMed
3. Singer, A. (2002) New perspectives on a developmental dilemma: the kinetic signaling model and the importance of signal duration for the CD4/CD8 lineage decision. Curr. Opin. Immunol. 14, 207-215 CrossRef PubMed
4. Drabsch, Y, Robert, R.G. and Gonda, T.J. (2010) MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res. 12, R55 CrossRef PubMed
5. Giani, C, Casalini, P., Pupa, S.M., De Vecchi, R., Ardini, E., Colnaghi, M.I., Giordano, A. and Menard, S. (1998) Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 17, 425-432 CrossRef PubMed
6. Nagashima, T, Shimodaira, H., Ide, K., Nakakuki, T, Tani, Y, Takahashi, K., Yumoto, N. and Hatakeyama, M. (2007) Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation. J. Biol. Chem. 282, 4045-4056 CrossRef PubMed
7. Bacus, S.S., Huberman, E., Chin, D., Kiguchi, K., Simpson, S., Lippman, M. and Lupu, R. (1992) A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ. 3, 401-411 PubMed
8. Chamras, H., Ardashian, A., Heber, D. and Glaspy, J.A. (2002) Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J. Nutr. Biochem. 13, 711-716 CrossRef PubMed
9. Martirosyan, A.R., Rahim-Bata, R., Freeman, A.B., Clarke, CD., Howard, R.L. and Strobl, J.S. (2004) Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model. Biochem. Pharmacol. 68, 1729-1738 CrossRef PubMed
10. Kim, K.Y., Kim, S.S. and Cheon, H.G. (2006) Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem. Pharmacol. 72, 530-540 CrossRef PubMed
11. Guilbaud, N.F., Gas, N., Dupont, M.A. and Valette, A. (1990) Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J. Cell. Physiol. 145, 162-172 CrossRef PubMed
12. Earp, H.S., Dawson, T.L., Li, X. and Yu, H. (1995) Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 35, 115-132 CrossRef PubMed
13. Lemmon, M.A. and Schlessinger, J. (2010) Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 CrossRef PubMed
14. Yarden, Y. and Sliwkowski, M.X. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2, 127-137 CrossRef PubMed
15. Birtwistle, M.R., Hatakeyama, M., Yumoto, N., Ogunnaike, B.A., Hoek, J.B. and Kholodenko, B.N. (2007) Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol. Syst. Biol. 3, 144 CrossRef PubMed
16. Bayascas, J.R. (2008) Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. Cell Cycle 7, 2978-2982 CrossRef PubMed
17. Mora, A., Komander, D., van Aalten, D.M. and Alessi, D.R. (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161-170 CrossRef PubMed
18. Sarbassov, D.D., Guertin, D.A., Ali, S.M. and Sabatini, D.M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 CrossRef PubMed
19. Zoncu, R., Efeyan, A. and Sabatini, D.M. (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell. Biol. 12, 21-35 CrossRef PubMed
20. Dowling, R.J., Topisirovic, I., Fonseca, B.D. and Sonenberg, N. (2010) Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta 1804, 433-439 CrossRef PubMed
21. Heikamp, E.B. and Powell, J.D. (2012) Sensing the immune microenvironment to coordinate T cell metabolism, differentiation & function. Semin. Immunol. 24, 414-420 CrossRef PubMed
22. Yu, W., Chen, Z., Zhang, J., Zhang, L., Ke, H., Huang, L., Peng, Y., Zhang, X., Li, S., Lahn, B.T. and Xiang, A.P. (2008) Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol. Cell. Biochem. 310, 11-18 CrossRef PubMed
23. Xiang, X., Zhao, J., Xu, G., Li, Y. and Zhang, W. (2011) mTOR and the differentiation of mesenchymal stem cells. Acta Biochim. Biophys. Sin. 43, 501-510 CrossRef
24. Kolch, W., Calder, M. and Gilbert, D. (2005) When kinases meet mathematics: the systems biology of MAPK signalling. FEBS Lett. 579, 1891-1895 CrossRef PubMed
25. Volinsky, N. and Kholodenko, B.N. (2013) Complexity of receptor tyrosine kinase signal processing. Cold Spring Harb. Perspect. Biol. 5, a009043 CrossRef PubMed
26. Aksamitiene, E., Kiyatkin, A. and Kholodenko, B.N. (2012) Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem. Soc. Trans. 40, 139-146 CrossRef PubMed
27. Borisov, N., Aksamitiene, E., Kiyatkin, A., Legewie, S., Berkhout, J., Maiwald, T., Kaimachnikov, N.P., Timmer, J., Hoek, J.B. and Kholodenko, B.N. (2009) Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol. Syst. Biol. 5, 256 CrossRef PubMed
28. Li, L. and Ross, A.H. (2007) Why is PTEN an important tumor suppressor? J. Cell. Biochem. 102, 1368-1374 CrossRef PubMed
29. Song, M.S., Salmena, L. and Pandolfi, P.P. (2012) The functions and regulation of the PTEN tumour suppressor. Nature reviews. Mol. Cell Biol. 13, 283-296
30. Huang, J. and Manning, B.D. (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217-222 CrossRef PubMed
31. Chresta, C.M., Davies, B.R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S.E., Vincent, J.P., Ellston, R., Jones, D., Sini, P. et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288-298 CrossRef PubMed
32. Ishizawar, R.C., Miyake, T. and Parsons, S.J. (2007) c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 26, 3503-3510 CrossRef PubMed
33. Michels, S., Trautmann, M., Sievers, E., Kindler, D., Huss, S., Renner, M., Friedrichs, N., Kirfel, J., Steiner, S., Endl, E. et al. (2013) SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Res. 73, 2518-2528 CrossRef PubMed
34. Finn, R.S. (2008) Targeting Src in breast cancer. Ann. Oncol. 19, 1379-1386 CrossRef PubMed
35. Kmiecik, T.E. and Shalloway, D. (1987) Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell 49, 65-73 CrossRef PubMed
36. Roskoski, Jr, R. (2005) Src kinase regulation by phosphorylation and dephosphorylation. Biochem. Biophys. Res. Commun. 331, 1-14 CrossRef PubMed
37. Bougeret, C., Jiang, S., Keydar, I. and Avraham, H. (2001) Functional analysis of Csk and CHK kinases in breast cancer cells. J. Biol. Chem. 276, 33711-33720 CrossRef PubMed
38. Baumann, J., Sevinsky, C. and Conklin, D.S. (2013) Lipid biology of breast cancer. Biochim. Biophys. Acta 1831, 1509-1517 CrossRef PubMed
39. Vander Heiden, M.G., Cantley, L.C. and Thompson, C.B. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 CrossRef PubMed
40. Zaidi, N., Swinnen, J.V. and Smans, K. (2012) ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 72, 3709-3714 CrossRef PubMed
41. Potapova, I.A., El-Maghrabi, M.R., Doronin, S.V. and Benjamin, W.B. (2000) Phosphorylation of recombinant human ATP: citrate lyase by cAMP-dependent protein kinase abolishes homotropic allosteric regulation of the enzyme by citrate and increases the enzyme activity. Allosteric activation of ATP: citrate lyase by phosphorylated sugars. Biochemistry 39, 1169-1179 CrossRef PubMed
42. Berwick, D.C., Hers, I., Heesom, K.J., Moule, S.K. and Tavare, J.M. (2002) The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J. Biol. Chem. 277, 33895-33900 CrossRef PubMed
43. Migita, T., Narita, T., Nomura, K., Miyagi, E., Inazuka, F., Matsuura, M., Ushijima, M., Mashima, T., Seimiya, H., Satoh, Y. et al. (2008) ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 68, 8547-8554 CrossRef PubMed
44. Soupene, E. and Kuypers, F.A. (2008) Mammalian long-chain acyl-CoA synthetases. Exp. Biol. Med. 233, 507-521 CrossRef
45. Schoonjans, K., Staels, B. and Auwerx, J. (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37, 907-925 PubMed
46. Rakhshandehroo, M., Hooiveld, G., Muller, M. and Kersten, S. (2009) Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 4, e6796 CrossRef PubMed
47. Kanter, J.E., Kramer, F., Barnhart, S., Averill, M.M., Vivekanandan-Giri, A., Vickery, T., Li, L.O., Becker, L., Yuan, W., Chait, A. et al. (2012) Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc. Natl. Acad. Sci. U.S.A. 109, E715-E724 CrossRef PubMed
48. Martin, G., Schoonjans, K., Lefebvre, A.M., Staels, B. and Auwerx, J. (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J. Biol. Chem. 272, 28210-28217 CrossRef PubMed
49. Rubinow, K.B., Wall, V.Z., Nelson, J., Mar, D., Bomsztyk, K., Askari, B., Lai, M.A., Smith, K.D., Han, M.S., Vivekanandan-Giri, A. et al. (2013) Acyl-CoA synthetase 1 is induced by Gram-negative bacteria and lipopolysaccharide and is required for phospholipid turnover in stimulated macrophages. J. Biol. Chem. 288, 9957-9970 CrossRef PubMed
50. Bionaz, M. and Loor, J.J. (2008) Gene networks driving bovine milk fat synthesis during the lactation cycle. BMC Genomics 9, 366 CrossRef PubMed
51. Lanzavecchia, A. and Sallusto, F. (2001) Antigen decoding by T lymphocytes: from synapses to fate determination. Nat. Immunol. 2, 487-492 CrossRef PubMed
52. Nagano, M.C. and Yeh, J.R. (2013) The identity and fate decision control of spermatogonial stem cells: where is the point of no return? Curr. Top. Dev. Biol. 102, 61-95 CrossRef PubMed
53. Welinder, E., Ahsberg, J. and Sigvardsson, M. (2011) B-lymphocyte commitment: identifying the point of no return. Semin. Immunol. 23, 335-340 CrossRef PubMed
54. Menendez, J.A. and Lupu, R. (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763-777 CrossRef PubMed
55. McManaman, J.L. (2014) Lipid transport in the lactating mammary gland. J. Mammary Gland Biol. Neoplasia 19, 35-42 CrossRef PubMed
56. Menendez, J.A., Vellon, L., Mehmi, I., Oza, B.P., Ropero, S., Colomer, R. and Lupu, R. (2004) Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 101, 10715-10720 CrossRef PubMed
57. Milgraum, L.Z., Witters, L.A., Pasternack, G.R. and Kuhajda, F.P. (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin. Cancer Res. 3, 2115-2120 PubMed
58. Szutowicz, A., Kwiatkowski, J. and Angielski, S. (1979) Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br. J. Cancer. 39, 681-687 CrossRef PubMed
59. Furuta, E., Okuda, H., Kobayashi, A. and Watabe, K. (2010) Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta 1805, 141-152 PubMed
60. Kuhajda, F.P., Jenner, K., Wood, F.D., Hennigar, R.A., Jacobs, L.B., Dick, J.D. and Pasternack, G.R. (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 6379-6383 CrossRef PubMed
61. Kuhajda, F.P., Piantadosi, S. and Pasternack, G.R. (1989) Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N. Engl. J. Med. 321, 636-641 CrossRef PubMed
62. Pitroda, S.P., Khodarev, N.N., Beckett, M.A., Kufe, D.W. and Weichselbaum, R.R. (2009) MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc. Natl. Acad. Sci. U.S.A. 106, 5837-5841 CrossRef PubMed
63. Zaytseva, Y.Y., Rychahou, P.G., Gulhati, P., Elliott, V.A., Mustain, W.C., O'Connor, K., Morris, A.J., Sunkara, M., Weiss, H.L., Lee, E.Y. and Evers, B.M. (2012) Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 72, 1504-1517 CrossRef PubMed
64. Bauer, D.E., Hatzivassiliou, G., Zhao, F., Andreadis, C. and Thompson, C.B. (2005) ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24, 6314-6322 CrossRef PubMed
65. Chypre, M., Zaidi, N. and Smans, K. (2012) ATP-citrate lyase: a mini-review. Biochem. Biophys. Res. Commun. 422, 1-4 CrossRef PubMed
66. Wellen, K.E., Hatzivassiliou, G., Sachdeva, U.M., Bui, T.V., Cross, J.R. and Thompson, C.B. (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076-1080 CrossRef PubMed
67. Hanai, J., Doro, N., Sasaki, A.T., Kobayashi, S., Cantley, L.C., Seth, P. and Sukhatme, V.P. (2012) Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J. Cell. Physiol. 227, 1709-1720 CrossRef PubMed
68. Hanai, J.I., Doro, N., Seth, P. and Sukhatme, V.P. (2013) ATP citrate lyase knockdown impacts cancer stem cells in vitro. Cell Death Dis. 4, e696 CrossRef PubMed
69. Lin, R., Tao, R., Gao, X., Li, T., Zhou, X., Guan, K.L., Xiong, Y. and Lei, Q.Y. (2013) Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol. Cell 51, 506-518 CrossRef PubMed
70. Boldt, S., Weidle, U.H. and Kolch, W. (2002) The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23, 1831-1838 CrossRef PubMed
71. Karam, M., Legay, C., Auclair, C. and Ricort, J.M. (2012) Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway. Exp. Cell Res. 318, 558-569 CrossRef PubMed
72. Martini, M., De Santis, M.C., Braccini, L., Gulluni, F. and Hirsch, E. (2014) PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 46, 372-383 CrossRef PubMed
73. Cairns, R.A., Harris, I.S. and Mak, T.W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95 CrossRef PubMed
74. Dillon, R.L., White, D.E. and Muller, W.J. (2007) The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26, 1338-1345 CrossRef PubMed
75. Albert, J.M., Kim, K.W., Cao, C. and Lu, B. (2006) Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol. Cancer Ther. 5, 1183-1189 CrossRef PubMed
76. Vandermoere, F., El Yazidi-Belkoura, I., Adriaenssens, E., Lemoine, J. and Hondermarck, H. (2005) The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene 24, 5482-5491 CrossRef PubMed
77. Gibson, S., Tu, S., Oyer, R., Anderson, S.M. and Johnson, G.L. (1999) Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J. Biol. Chem. 274, 17612-17618 CrossRef PubMed